| Name | Title | Contact Details |
|---|---|---|
Dan Jamieson |
Associate Director Enterprise Architecture | Profile |
Diana Atwell |
Associate Director, Information Systems | Profile |
Conagen is a #syntheticbiology leader, supporting our global partners through #enzymatic and #microbial platforms and #biomanufacturing capabilities.
Sage Therapeutics is a clinical-stage biopharmaceutical company committed to developing novel medicines to transform the lives of patients with life-altering central nervous system (CNS) disorders. Sage`s lead product candidate, ZULRESSO(TM) (brexanolone) injection, has completed Phase 3 clinical development for postpartum depression and a New Drug Application is currently under review with the U.S. Food and Drug Administration. Sage is developing a portfolio of novel product candidates targeting critical CNS receptor systems, including SAGE-217, which is in Phase 3 development in major depressive disorder and postpartum depression.
Blaze Bioscience, Inc. is a privately held biotechnology company focused on guided therapies. Blaze was founded in 2010 by Dr. Jim Olson, a pediatric neuro-oncologist at the Fred Hutchinson Cancer Research Center and Seattle Children`s Hospital, and Heather Franklin, a former senior business executive from ZymoGenetics. Blaze is working to develop Tumor Paint products and Optide*-based guided therapeutics.
Thallion Pharmaceuticals is a Saint-Laurent, QC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Q Therapeutics is a Salt Lake City, UT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.